RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME)

Anti‐D immune globulin (RhIG) is a front‐line option in North America for the treatment of immune thrombocytopenia (ITP) in children and adults. Recently, addition of a Food and Drug Administration‐mandated black box warning highlighted the risks of intravascular hemolysis, renal failure, and dissem...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Transfusion (Philadelphia, Pa.) Pa.), 2012-05, Vol.52 (5), p.1126-1136
Hauptverfasser:	Despotovic, Jenny M., Lambert, Michele P., Herman, Jay H., Gernsheimer, Terry B., McCrae, Keith R., Tarantino, Michael D., Bussel, James B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis Drug toxicity and drugs side effects treatment Hemolysis Humans Immunoglobulins, Intravenous - therapeutic use Medical sciences Pharmacology. Drug treatments Purpura, Thrombocytopenic, Idiopathic - drug therapy Rho(D) Immune Globulin - adverse effects Rho(D) Immune Globulin - therapeutic use Toxicity: blood Transfusions. Complications. Transfusion reactions. Cell and gene therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!